Rhenman & Partners Asset Management’s Immunovant IMVT Stock Holding History

Rhenman & Partners Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25,924	Closed	-$443K	–	101
2025 Q1	$443K	Sell	25,924 -119,076	-82%	-$2.49M	0.05%	94
2024 Q4	$3.59M	Sell	145,000 -98,000	-40%	-$2.78M	0.37%	64
2024 Q3	$6.93M	Buy	243,000 +112,500	+86%	+$3.32M	0.56%	56
2024 Q2	$3.45M	Buy	130,500 +5,000	+4%	+$142K	0.33%	68
2024 Q1	$4.05M	Sell	125,500 -20,561	-14%	-$750K	0.38%	57
2023 Q4	$6.15M	Sell	146,061 -20,000	-12%	-$736K	0.61%	53
2023 Q3	$6.38M	Buy	166,061 +66,061	+66%	+$1.49M	0.69%	43
2023 Q2	$1.9M	Buy	+100,000	New	+$1.86M	0.2%	75

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Rhenman & Partners Asset Management's IMVT Position: Q2 2025 in Review

Rhenman & Partners Asset Management sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 25,924 shares — an estimated $443K sold.

Rhenman & Partners Asset Management first reported a position in IMVT in Q2 2023 and held it in 8 quarters. The position peaked at $6.93M in Q3 2024. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

Rhenman & Partners Asset Management reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
Rhenman & Partners Asset Management sold 25,924 Immunovant shares in Q2 2025, an estimated $443K.
Rhenman & Partners Asset Management first reported a position in Immunovant in Q2 2023 and held it in 8 quarters.
Rhenman & Partners Asset Management's Immunovant position peaked at $6.93M in Q3 2024.
168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.